Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$10.83 - $18.41 $189,525 - $322,175
-17,500 Reduced 69.44%
7,700 $104,000
Q4 2020

Feb 11, 2021

BUY
$15.77 - $19.03 $302,784 - $365,376
19,200 Added 320.0%
25,200 $428,000
Q3 2020

Nov 12, 2020

SELL
$16.59 - $24.79 $18,249 - $27,269
-1,100 Reduced 15.49%
6,000 $100,000
Q2 2020

Aug 12, 2020

SELL
$16.86 - $23.44 $915,498 - $1.27 Million
-54,300 Reduced 88.44%
7,100 $164,000
Q1 2020

May 13, 2020

SELL
$14.47 - $27.96 $1.21 Million - $2.35 Million
-83,900 Reduced 57.74%
61,400 $1.1 Million
Q4 2019

Feb 10, 2020

BUY
$15.87 - $23.12 $112,677 - $164,152
7,100 Added 5.14%
145,300 $3.14 Million
Q3 2019

Nov 14, 2019

SELL
$16.91 - $36.27 $610,451 - $1.31 Million
-36,100 Reduced 20.71%
138,200 $2.52 Million
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $1.25 Million - $1.47 Million
40,400 Added 30.17%
174,300 $6.2 Million
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $258,956 - $380,070
-8,200 Reduced 5.77%
133,900 $4.5 Million
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $1.11 Million - $2.07 Million
-36,600 Reduced 20.48%
142,100 $4.67 Million
Q3 2018

Nov 14, 2018

SELL
$46.46 - $68.49 $4 Million - $5.9 Million
-86,100 Reduced 32.52%
178,700 $10.9 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $8.69 Million - $19.6 Million
187,900 Added 244.34%
264,800 $12.9 Million
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $1.9 Million - $3.59 Million
-33,100 Reduced 30.09%
76,900 $8.17 Million
Q4 2017

Feb 14, 2018

SELL
$23.02 - $60.5 $108,194 - $284,350
-4,700 Reduced 4.1%
110,000 $6.57 Million
Q3 2017

Nov 14, 2017

BUY
$17.79 - $24.0 $2.04 Million - $2.75 Million
114,700
114,700 $2.75 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $201M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.